Figure 3 Proliferation assay using quantitative ELISA analysis of BrdU incorporation into choroidal endothelial (A), ARPE19 (B), and RGC5 (C) cells during exposure to various concentrations of bevacizumab. The anti‐proliferative activity was determined after 1 day of treatment. The assay revealed a significant antiproliferative effect of bevacizumab on choroidal cells. Apart from that a decrease of BrdU incorporation into ARPE19 cells was noted in the presence of 2.5 mg/ml bevacizumab. The proliferation rate of RGC5 cells was not affected by bevacizumab. Asterisk indicates a statistically significant difference (p<0.05).